Balchem $(BCPC)$ reported Q4 FY2025 net sales of USD 263.6 million (+9.8%), net earnings of USD 39.2 million (+16.8%), adjusted EBITDA of USD 67.9 million (+8.1%), and free cash flow of USD 51.2 million. Q4 diluted EPS was USD 1.21 and adjusted diluted EPS was USD 1.31. For FY2025, Balchem posted net sales of USD 1.04 billion (+8.8%), net earnings of USD 154.8 million (+20.5%), adjusted EBITDA of USD 274.9 million (+9.8%), and free cash flow of USD 173.6 million. FY2025 diluted EPS was USD 4.75 and adjusted diluted EPS was USD 5.15. By segment in Q4 FY2025, Human Nutrition and Health sales were USD 166.1 million, Animal Nutrition and Health sales were USD 61.2 million, and Specialty Products sales were USD 34.8 million. Management cited year-over-year sales and earnings from operations growth across all three segments, with Human Nutrition and Health growth driven by higher sales in nutrients and food ingredients and solutions, and Specialty Products growth driven by higher performance gases sales. Balchem also reported Q4 share repurchases of USD 53.6 million and ended FY2025 with USD 74.6 million in cash and USD 164 million outstanding on its revolving loan.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Balchem Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9658309-en) on February 20, 2026, and is solely responsible for the information contained therein.
Comments